What are the chances we presently have of carrying a cardiovascular disease at some point in our lives?

Original title: Lifetime Risk and Years Lived Free of Total Cardiovascular Disease Reference: John T. Wilkins et al. JAMA. 2012; 308(17):1795-1801.

This study analyzed more than 120,000 patients in the cohorts of large community studies, such as the Framingham, who did not have cardiovascular disease at the time of inclusion 

Considering all the age subgroups, only between 1.7% and 7.9% were within the optimal range of risk factors, (BP <120/80 mmHg, total cholesterol

In contrast, more than 55% of the population had one or two risk factors analyzed whatever their age. With this data it was possible to calculate, for example, that a 45 year-old man with no history has a 60.3% risk of contracting a cardiovascular disease at some point in his life.

For a woman of the same age the risk factor is 55.6%. In a middle age, a person with optimal risk control factors has an estimated 14 more years of free cardiovascular disease than someone of the same age with 2 risk factors. However, despite the likelihood of optimal control of risk, the odds of contracting an illness are still above 30%.

Editorial Comment: 

This study shows the enormous prevalence of cardiovascular disease and that this will continue to rise beyond the level that medical treatment can manage. Dealing with this huge number of patients is not only going to be a challenge for us in the catheterization laboratory but also an enormous public health problem.

SOLACI.ORG

More articles by this author

Polymer-Free vs. Biodegradable Polymer Stents: SORT OUT IX 5-Year Outcomes

In a constant strive to achieve life time management, interventional cardiologists focus on optimizing coronary scaffolds, which calls for the development of devices with...

Chronic Stent Recoil and Its Long-Term Effects

The evolution of stent technology—including new scaffold designs, thinner struts, and more biocompatible polymers—has brought about an emerging concern: the late loss of structural...

PROSPECT II Substudy: Relationship Between Different Levels of hs-CRP and Vulnerable Plaque Characteristics in Patients with NSTEMI

Inflammation plays a key role in the onset and progression of atherosclerosis and has been linked to a higher risk of cardiovascular events, regardless...

Aspirin vs. Clopidogrel Monotherapy After 1 Month of ACS: Subgroup Analysis Based on Bleeding Risk and MI Type

Current guidelines still recommend dual antiplatelet therapy (DAPT) for 12 months following percutaneous coronary intervention (PCI) as the standard treatment in patients with acute...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Polymer-Free vs. Biodegradable Polymer Stents: SORT OUT IX 5-Year Outcomes

In a constant strive to achieve life time management, interventional cardiologists focus on optimizing coronary scaffolds, which calls for the development of devices with...

Three-Year Outcomes of Mitral Valve-in-Valve Therapy with Balloon-Expandable Valves in the United States

Gentileza del Dr. Juan Manuel Pérez. Mitral Valve-in-Valve (MViV) implantation with balloon-expandable valves has become a solid alternative for patients with degenerated mitral bioprostheses. However,...

Edge-to-Edge Treatment in Cardiogenic Shock

Cardiogenic shock (CS) is characterized by severe ventricular dysfunction, most often of ischemic origin. It is frequently associated with severe mitral regurgitation (MR), either...